Jackson, M.D. v. NuVasive, Inc.

CourtDistrict Court, D. Delaware
DecidedMay 30, 2023
Docket1:21-cv-00053
StatusUnknown

This text of Jackson, M.D. v. NuVasive, Inc. (Jackson, M.D. v. NuVasive, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jackson, M.D. v. NuVasive, Inc., (D. Del. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

ROGER P. JACKSON, M.D., Plaintiff, Vv. Civil Action No. 21-53-RGA NUVASIVE, INC., Defendant.

MEMORANDUM OPINION Stephen J. Kraftschik, POLSINELLI PC, Wilmington, DE; Thomas Gemmell, POLSINELLI PC, Chicago, IL; Darren E. Donnelly, POLSINELLI LLP, San Francisco, CA; Aaron M. Levine (argued), POLSINELLI PC, Houston, TX. Attorneys for Plaintiff.

Damiel M. Silver, Alexandra M. Joyce, MCCARTER & ENGLISH, LLP, Wilmington, DE; Colin G. Cabral (argued), James R. Anderson, PROSKAUER ROSE LLP, Boston, MA; Jessica M. Griffith, PROSKAUER ROSE LLP, Los Angeles, CA. Attorneys for Defendant.

May N , 2023

Before me is the issue of claim construction of a single term in U.S. Patent Nos. 9,788,866 (“the *866 patent”), 10,722,273 (“the °273 patent”), and 11,051,856 (“the ’856 patent”) (“the Asserted Markman Patents”).'! The parties submitted a Joint Claim Construction Brief (D.I. 110) and Appendix (D.I. 111), and I heard oral argument on May 19, 2023 (Markman Tr. ’). 1. BACKGROUND On January 19, 2021, Plaintiff Dr. Jackson filed his Complaint alleging infringement of the °866 and ’273 patents, among others, against Defendant NuVasive, Inc. (“NuVasive”). (D.I. 1). On July 21, 2021, Plaintiff filed his First Amended Complaint additionally alleging infringement of the °856 patent. (D.I. 17). On October 21, 2022, Plaintiff filed his Second Amended Complaint, the amendments to which are not relevant to this opinion (D.I. 77). The ’866 and ’273 patents belong to the same patent family and share a specification. The patent has a different specification, but all three patents are directed to a compression or pressure insert in spinal implant systems that fixes the rod and screw components of a spinal stabilization system in place. (°866 patent, 2:8—15; °856 patent, 3:42-48). Il. LEGAL STANDARD “Tt is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc) (internal quotation marks omitted). “‘[T]here is no magic formula or catechism for conducting claim construction.’ Instead, the court is free to attach the appropriate

! The parties also disputed claim terms in U.S. Patent No. 10,561,444 (“the ’444 patent”) and U.S. Patent No. 9,808,292 (“the ’292 patent”) but resolved all disputes regarding those patents prior to oral argument. ? Citations to the transcript of the argument, which is not yet docketed, are in the format “Markman Tr. _.”

weight to appropriate sources ‘in light of the statutes and policies that inform patent law.’” SofitView LLC vy. Apple Inc., 2013 WL 4758195, at *1 (D. Del. Sept. 4, 2013) (quoting Phillips, 415 F.3d at 1324) (alteration in original). When construing patent claims, a court considers the literal language of the claim, the patent specification, and the prosecution history. Markman v. Westview Instruments, Inc., 52 F.3d 967, 977-80 (Fed. Cir. 1995) (en banc), aff'd, 517 U.S. 370 (1996). Of these sources, “the specification is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.” Phillips, 415 F.3d at 1315 (internal quotation marks omitted). “{T]he words of a claim are generally given their ordinary and customary meaning... . [Which is] the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Jd. at 1312-13 (citations and internal quotation marks omitted). “[T]he ordinary meaning ofa claim term is its meaning to [an] ordinary artisan after reading the entire patent.” /d. at 1321 (internal quotation marks omitted). “In some cases, the ordinary meaning of claim language as understood by a person of skill in the art may be readily apparent even to lay judges, and claim construction in such cases involves little more than the application of the widely accepted meaning of commonly understood words.” /d. at 1314. When a court relies solely upon the intrinsic evidence—the patent claims, the specification, and the prosecution history—the court’s construction is a determination of law. See Teva Pharm. USA, Inc. v. Sandoz, Inc., 574 U.S. 318, 331 (2015). The court may also make factual findings based upon consideration of extrinsic evidence, which “consists of all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” Phillips, 415 F.3d at 1317-19 (internal quotation marks omitted). Extrinsic evidence

may assist the court in understanding the underlying technology, the meaning of terms to one skilled in the art, and how the invention works. /d. Extrinsic evidence, however, is less reliable and less useful in claim construction than the patent and its prosecution history. Jd. II. PATENTS AT ISSUE The ’866 and ’273 patents have a priority date of May 27, 2005. The °856 patent has a priority date of October 30, 2007. Plaintiff is asserting the following claims of the Asserted Markman Patents: claims | and 9 of the ’866 patent, claims 1, 12, 15 and 35 of the ’273 patent, and claims 1 and 9 of the ’856 patent. (D.I. 110 at 6-7). The following claims are representative and most relevant for purposes of claim construction: Claim 1 of the ’866 Patent 1. A bone anchor assembly for securing an elongate rod to a bone, the bone anchor assembly comprising: a shank having a proximal capture portion and an anchor portion extending distally from the proximal capture portion for fixation to the bone; a receiver having a longitudinal axis, an upper portion defining a U-shaped channel with inner sidewall surfaces configured to receive the elongate rod, and a lower portion defining a cavity communicating with the U-shaped channel and a receiver bottom opening for receiving the proximal capture portion of the shank therethrough, the inner sidewall surfaces including a guide and advancement structure and a discontinuous downward- facing shoulder formed therein between the guide and advancement structure and the cavity; a retainer sized and shaped for loading into the cavity to engage and hold the shank proximal capture portion in spaced relation with respect to the receiver while an outer surface of the retainer engages an interior surface of the cavity to allow a pivotal motion between the receiver and the shank; and a pressure insert sized and shaped to be positioned downwardly within the receiver into a first position, the pressure insert having upward-facing contact surfaces and being rotatable with a tool into a second position that locates the upward-facing contact surfaces under the discontinuous downward-facing shoulder of the receiver to prevent the: pressure insert from moving back up within the receiver. patent at 29:41—30:3 (disputed term italicized and bolded)). Claims 12 and 35 of the ’273 Patent 12. A bone anchor assembly for securing an elongate rod to a bone, the bone anchor assembly comprising:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Jackson, M.D. v. NuVasive, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/jackson-md-v-nuvasive-inc-ded-2023.